New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2013
18:36 EDTALNYAlnylam aims to advance ALN-TTR02 into Phase III pivotal trial
Alnylam aims to advance ALN-TTR02 into Phase III pivotal trial in Transthyretin, TTR -mediated amyloidosis, ATTR, Patients with Familial Amyloidotic Polyneuropathy, FAP, by late 2013; Phase II data expected in mid-2013.
News For ALNY From The Last 14 Days
Check below for free stories on ALNY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 21, 2014
09:16 EDTALNYAlnylam to hold a roundtable webinar
Subscribe for More Information
August 20, 2014
08:07 EDTALNYAlnylam receives USPTO notice of allowance for new patent
Alnylam Pharmaceuticals announced that the United States Patent and Trademark Office has issued a Notice of Allowance for claims in the Tuschl et al. patent application 13/725,262. The ’262 patent application includes newly allowed claims directed to compositions that mediate RNAi, and comprising a double-stranded molecule with up to 25 base pairs and at least one nucleotide analogue. Specifically, the newly allowed patent application broadly covers small interfering RNA molecules of various designs, including so-called “dicer substrate” RNAi triggers (Amarzguioui et al., Nat Protoc. 2006;1(2):508-17; Rose et al., Nucleic Acids Res. 2005 Jul 26;33(13):4140-56) and double-stranded, RNAi-mediating molecules containing moieties that include “unlocked nucleobase analogs” amongst other naturally or non-naturally occurring nucleotide analogues. The allowed claims of the Tuschl ’262 patent application, as well as other granted, Alnylam-owned or -licensed patents, in aggregate broadly cover compositions, methods, and uses of RNAi therapeutics.
August 19, 2014
15:50 EDTALNYAlnylam to hold a roundtable webinar
Subscribe for More Information
August 14, 2014
07:24 EDTALNYAlnylam to hold a roundtable webinar
Subscribe for More Information
August 13, 2014
06:29 EDTALNYAlnylam called at top mid-cap pick for second half at Piper Jaffray
Piper Jaffray calls Alnylam a top mid-cap pick for the second half of 2014 and reiterates an Overweight rating on the name with a $101 price target. Piper thinks shares can rally into 2015 based on data read-outs and pipeline expansion.
August 12, 2014
15:55 EDTALNYAlnylam to hold a roundtable webinar
Subscribe for More Information
August 7, 2014
16:02 EDTALNYAlnylam reports Q2 EPS (63c), consensus (56c)
Subscribe for More Information
15:33 EDTALNY Notable companies reporting after market close
Subscribe for More Information
15:31 EDTALNYNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include CBS (CBS), consensus 72c; Consolidated Edison (ED), consensus 54c; Monster Beverage (MNST), consensus 75c; News Corporation (NWSA), consensus 3c; NVIDIA (NVDA), consensus 20c; Computer Sciences (CSC), consensus 94c; CareFusion (CFN), consensus 72c;DeVry Education (DV), consensus 67c; Salix Pharmaceuticals (SLXP), consensus $1.72; Federal Realty (FRT), consensus $1.21; SolarCity (SCTY), consensus (99c); Medivation (MDVN), consensus 24c; Sprouts Farmers Market (SFM), consensus 18c; Alnylam Pharmaceuticals (ALNY), consensus (56c); Lions Gate (LGF), consensus 17c; Mercadolibre (MELI), consensus 56c; Post Holdings (POST), consensus 27c; Assured Guaranty (AGO), consensus 35c; Great Plains Energy (GXP), consensus 41c; Air Lease (AL), consensus 52c; Ubiquiti Networks (UBNT), consensus 51c; SemGroup (SEMG), consensus 35c.
08:11 EDTALNYAlnylam receives orphan drug designations in EU for ALN-AT3
Subscribe for More Information
07:31 EDTALNYAlnylam to hold a roundtable webinar
Roundtable where Alnylam scientists and key clinical collaborators review recent progress from several of the "Alnylam 5x15" programs and discuss the related disease areas will be held on August 7 at 9:30 am. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use